Celyad Oncology SA (CYAD.BR) Comparison with companies in other sectors?

Celyad Oncology SA has a share price of 41.43M. You can analyze Celyad Oncology SA (CYAD.BR) competitors across different market sectors through stock heatmaps.

What are CYAD.BR's NET and operating margins?

Celyad Oncology SA (CYAD.BR) operating margin is around -32.65, and net profit margin is approximately -31.31 as of the latest reports.

In what way does CYAD.BR's earnings per share (EPS) trend reflect its financial momentum?

Celyad Oncology SA (CYAD.BR) EPS is -1.36 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Celyad Oncology SA is -0.26, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Celyad Oncology SA?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Celyad Oncology SA like P/E which is -2.49, P/B which is -0.90, and PEG which is -0.08. Compare them with sector averages to evaluate if the stock is priced fairly.

Celyad Oncology SA

CYAD.BR•EURONEXT

Healthcare

Biotechnology

€0.35

€-0.02(-4.37%)

Fundamental Analysis of Celyad Oncology SA (CYAD.BR)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-1.36

P/E Ratio

-0.26

ROE

0.91%

Net Margin

-31.31%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$14.50M

Shares OutstandingTotal number of shares issued

$41.43M

Book Value/ShareNet worth per share

$-0.39

Revenue/ShareAnnual revenue per share

$0.004

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-1.36

Net MarginNet income as percentage of revenue

-3130.65%

Operating MarginOperating income as percentage of revenue

-3265.05%

ROEReturn on shareholders' equity

90.60%

ROAReturn on total assets

-58.65%

ROCEReturn on capital employed

-85.75%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.25

Cash/ShareCash and equivalents per share

$0.10

FCF YieldFree cash flow as percentage of market cap

-70.93%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for CYAD.BRFinancial Ratios Analysis details for CYAD.BR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for CYAD.BRSector Benchmarking details for CYAD.BR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Celyad Oncology SA Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Celyad Oncology SA. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Celyad Oncology SA's unique business strengths and challenges.

Key Financial Metrics for Celyad Oncology SA

For Celyad Oncology SA, essential financial indicators include EPS -1.36, PE -0.26, and ROE 0.91. These key ratios reveal insights into Celyad Oncology SA's profitability, valuation, and operational health. Understanding these metrics enables you to compare Celyad Oncology SA with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Celyad Oncology SA

Metrics like Net Margin -3130.65% and ROA -58.65% shed light on how well Celyad Oncology SA is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Celyad Oncology SA can sustain its operations and continue growing in the future.

Valuation and Market Position of Celyad Oncology SA

Using ratios such as P/B Ratio -0.90 and PEG Ratio -0.08, investors can assess whether Celyad Oncology SA is appropriately valued based on its financials and growth potential. These figures, combined with Celyad Oncology SA's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Celyad Oncology SA

Financial health indicators, such as Debt/Equity Ratio -1.09 and Cash Flow $-0.25, provide a snapshot of Celyad Oncology SA's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Celyad Oncology SA, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Celyad Oncology SA

Investing in Celyad Oncology SA based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Celyad Oncology SA focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;